Placeholder Banner

BIO Comments on FDA Draft Guidance on Rare Diseases: Natural History Studies for Drug Development

May 24, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Rare Diseases: Natural History Studies for Drug Development.

BIO says the guidance is as an important communication tool for the FDA and Sponsors. It ensures Sponsors have the appropriate information for developing new therapies for patients with rare diseases ­– especially since many rare diseases do not have FDA-approved treatment.

BIO provides recommendations on how to improve natural history studies so the FDA can have robust data for making regulatory decisions, as well as how to improve the guidance. BIO recommends the draft guidance align with other draft guidance covering natural history studies, like Rare Diseases: Common Issues in Drug Development

 

Download Full Comments Below
BIO Comment Letter Natural History Studies Rare Disease Drug Development FDA–2017-D-0481
Read the full comment letter below
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…
  On behalf of the scientists and researchers the Biotechnology Innovation Organization (BIO) represents, I am writing to request that you publicly release all new guidance developed by the Food and Drug Administration (FDA) concerning…